title: Levels of angiogenic peptides in sera from patients with carcinoid tumours during alpha-interferon treatment.
abstract: BACKGROUND
  Alpha-interferon, a known inhibitor of angiogenesis and cell proliferation, is used in the standard treatment of patients with carcinoid tumors. We studied the levels of two angiogenic peptides (bFGF and VEGF) in sera from patients with carcinoid tumours before and during treatment with alpha-interferon. The aim was to investigate if the antitumoral effect of alpha-interferon in these patients could be at least in part explained by a reduction in the measured angiogenetic peptides.
  
  
  METHODS
  Sera from 29 patients with carcinoid tumours were collected before and during alpha-interferon treatment and analyzed using commercially available ELISA-kits.
  
  
  RESULTS
  Interferon alpha treatment did not cause reduction of bFGF and VEGF levels in serum from patients with carcinoid tumours. In fact there was no correlation between changes in bFGF or VEGF levels and treatment effect.
  
  
  CONCLUSIONS
  The action of alpha-interferon does not seem to be mediated by bFGF or VEGF in patients with carcinoid tumours. If alpha-interferon has an anti-angiogenic effect in this patient group, it is probably mediated by angiogenic peptides other than bFGF and VEGF.
authors.affiliation: Department of Medical Sciences, University Hospital, Uppsala, Sweden.
authors.forename: A
authors.initials: A
authors.lastname: Nilsson
authors.forename: E T
authors.initials: ET
authors.lastname: Janson
authors.forename: B
authors.initials: B
authors.lastname: Eriksson
authors.forename: A
authors.initials: A
authors.lastname: Larsson
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002276:Carcinoid Tumor / Q000097:blood* / Q000098:blood supply / Q000188:drug therapy*; D016228:Endothelial Growth Factors / Q000097:blood*; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000097:blood*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007414:Intestinal Neoplasms / Q000097:blood* / Q000098:blood supply / Q000188:drug therapy*; D008222:Lymphokines / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000097:blood / Q000188:drug therapy; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D016228:Endothelial Growth Factors; D016898:Interferon-alpha; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2